Drugplain

Zidovudine 100 mg/1

Zidovudine · CAPSULE · Aurobindo Pharma Limited

3 Recalls on Record
Plain English

Zidovudine is a capsule containing zidovudine at 100 mg/1, taken oral. Manufactured by Aurobindo Pharma Limited.

Key Facts

Brand Name
Zidovudine
Generic Name
Zidovudine
NDC Code (Product)
65862-107
Manufacturer
Aurobindo Pharma Limited
Strength
100 mg/1
Dosage Form
CAPSULE
Route
ORAL
Marketing Status
Application #
ANDA078128
Drug Class
Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]
Marketing Start
03/27/2006

Recall History

3 Recalls on Record
Class II06/04/2012

GlaxoSmithKline Inc

Adulterated Presence of Foreign Tablets: Trizivir 300/150/300 mg tables, Lot 0ZP5128 may incorrectly contain Lexiva 700 mg tablets.

TerminatedVoluntary: Firm initiated
Class II03/02/2015

American Health Packaging

Failed dissolution specifications

TerminatedVoluntary: Firm initiated
Class II11/14/2014

Attix Pharmaceuticals

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

TerminatedVoluntary: Firm initiated

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

foetal exposure during pregnancy1,712 reports
virologic failure850 reports
drug resistance733 reports
exposure during pregnancy650 reports
anaemia640 reports
pathogen resistance636 reports
viral mutation identified634 reports
drug exposure during pregnancy600 reports
premature baby527 reports
maternal exposure during pregnancy515 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

1 INDICATIONS & USAGE Lamivudine and zidovudine tablets a combination of 2 nucleoside analogues, are indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Lamivudine and zidovudine tablets, a combination of 2 nucleoside analogue reverse transcriptase inibitors, are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. (1)

Dosage & Administration

2 DOSAGE & ADMINISTRATION • Adults and Adolescents weighing greater than or equal to 30 kg: 1 tablet orally twice daily. (2.1) • Pediatrics weighing greater than or equal to 30 kg: 1 tablet orally twice daily. (2.2) • Because lamivudine and zidovudine tablet is a fixed-dose tablet and cannot be dose adjusted, lamivudine and zidovudine tablet is not recommended in patients requiring dosage adjustment or with hepatic impairment or experiencing dose-limiting adverse reactions. (2.3, 4) 2.1 Recommended Dosage for Adults and Adolescents The recommended dosage of lamivudine and zidovudine tablet in HIV-1-infected adults and adolescents weighing greater than or equal to 30 kg is 1 tablet (containing 150 mg of lamivudine and 300 mg of zidovudine) taken orally twice daily. 2.2 Recommended Dosage for Pediatric Patients The recommended dosage of scored lamivudine and zidovudine tablets for pediatric patients who weigh greater than or equal to 30 kg and for whom a solid oral dosage form is appropriate is 1 tablet administered orally twice daily. Before prescribing lamivudine and zidovudine tablets, children should be assessed for the ability to swallow tablets. If a child is unable to reliably

Contraindications

4 CONTRAINDICATIONS Lamivudine and zidovudine tablets are contraindicated in patients with a previous hypersensitivity reaction to lamivudine or zidovudine. Lamivudine and zidovudine tablets are contraindicated in patients with a previous hypersensitivity reaction to lamivudine or zidovudine. (4)

Drug Interactions

7 DRUG INTERACTIONS • Agents antagonistic with zidovudine: Concomitant use should be avoided. (7.1) • Hematologic/bone marrow suppressive/cytotoxic agents: May increase the hematologic toxicity of zidovudine. (7.1) • Sorbitol: Coadministration of lamivudine and sorbitol may decrease lamivudine concentrations; when possible, avoid chronic coadministration. (7.2) • Agents antagonistic with zidovudine: Concomitant use should be avoided. (7.1) • Hematologic/bone marrow suppressive/cytotoxic agents: May increase the hematologic toxicity of zidovudine. (7.1) • Sorbitol: Coadministration of lamivudine and sorbitol may decrease lamivudine concentrations; when possible, avoid chronic coadministration. (7.2) 7.1 Zidovudine Agents Antagonistic with Zidovudine Concomitant use of zidovudine with the following drugs should be avoided since an antagonistic relationship has been demonstrated in vitro : • Stavudine • Doxorubicine • Nucleoside analogues, e.g., ribavirin Hematologic/Bone Marrow Suppressive/Cytotoxic Agents Coadministration with the following drugs may increase the hematologic toxicity of zidovudine: • Ganciclovir • Interferon alfa • Ribavirin • Other bone marrow suppressive or cytoto

Adverse Reactions

6 ADVERSE REACTIONS The following adverse reactions are discussed in other sections of the labeling: • Hematologic toxicity, including neutropenia and anemia [see Boxed Warning, Warnings and Precautions (5.1)]. • Symptomatic myopathy [see Boxed Warning, Warnings and Precautions (5.2)]. • Lactic acidosis and severe hepatomegaly with steatosis [see Boxed Warning, Warnings and Precautions (5.3)]. • Exacerbations of hepatitis B [see Boxed Warning, Warnings and Precautions (5.4)]. • Hepatic decompensation in patients co-infected with HIV-1 and hepatitis C [see Warnings and Precautions (5.5)]. • Exacerbation of anemia in HIV-1/HCV co-infected patients receiving ribavirin and zidovudine [see Warnings and Precautions (5.5)]. • Pancreatitis [see Warnings and Precautions (5.6)]. • Immune reconstitution syndrome [see Warnings and Precautions (5.7)]. • Lipoatrophy [see Warnings and Precautions (5.8)]. • Most commonly reported adverse reactions (incidence greater than or equal to 15%) in clinical trials of combination lamivudine and zidovudine were headache, nausea, malaise and fatigue, nasal signs and symptoms, diarrhea, and cough. (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Hetero La

Frequently Asked Questions

What is Zidovudine used for?

Zidovudine contains Zidovudine. It is a capsule taken oral. Consult your doctor for specific uses.

Is Zidovudine a controlled substance?

Zidovudine is not classified as a controlled substance by the DEA.

What is the generic name for Zidovudine?

The generic name for Zidovudine is Zidovudine. There are 3 other brand versions of Zidovudine.

What is the NDC code for Zidovudine 100 mg/1?

The NDC (National Drug Code) for Zidovudine 100 mg/1 is 65862-107, listed by Aurobindo Pharma Limited.

Product NDC

65862-107

Package NDC

65862-107-01

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)